非小细胞肺癌血浆EGFR突变检测的价值主张
本文运用价值主张框架评估血浆EGFR突变检测在晚期或转移性非小细胞肺癌患者中指导EGFR酪氨酸激酶抑制剂治疗的价值。基于已发表关键证据,分析其临床有效性、经济影响和局限性,认为该检测对预测TKI治疗资格、实时监测、调整方案和追踪耐药至关重要,并在活检组织不足或不可及时带来临床与经济获益。
要点
- 血浆EGFR突变检测可指导晚期NSCLC患者TKI治疗决策。
- 该检测有助于实时监测疗效、调整方案和追踪耐药。
- 在组织活检不足或不可及时,血浆检测可减少组织活检并带来获益。
核心结论
- 血浆EGFR突变检测对指导晚期或转移性NSCLC患者的TKI治疗决策至关重要。
- 合理使用血浆EGFR突变检测可为诊疗路径中各利益相关方带来临床和经济获益。
研究设计与样本
- 应用价值主张框架,评估已发表的关键证据。
主要发现
- 血浆EGFR突变检测对预测个体患者TKI治疗资格、实时监测、调整治疗方案和追踪耐药至关重要。
- 在活检材料不足或不可获得的情况下,血浆EGFR突变检测可减少组织活检。
临床怎么用
- 在晚期或转移性NSCLC患者中,可考虑使用血浆EGFR突变检测指导TKI治疗。
- 当组织活检材料不足或不可获得时,血浆EGFR突变检测可作为替代或补充手段。
局限性
- 原文提及评估了该方法的局限性,但摘要未具体说明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Genomics-driven precision medicine using targeted therapies requires advanced molecular diagnostic tests. Decisions about the use and reimbursement for such tests are increasingly being made on the basis of more outcome-based and value-based approaches. The value proposition concept is a tool to assess the benefits of laboratory testing to each stakeholder of the care pathway with respect to outcomes. This concept was applied to the use of noninvasive plasma epidermal growth factor receptor (EGFR) mutation testing in patients with advanced or metastatic non-small cell lung cancer (NSCLC) to guide treatment with EGFR tyrosine kinase inhibitors (TKIs). Using the value proposition framework, we evaluated published key evidence regarding clinical validity, economic implications, and limitations of this approach. It has been shown that plasma EGFR mutation testing is essential for guiding clinical decisions regarding prediction of eligibility of individual patients for TKI treatment, real-time monitoring, or adjustment of treatment regimens and tracking resistance. The appropriate use of plasma EGFR mutation testing has been shown to deliver both clinical and economic benefits to stakeholders across the entire care pathway; especially in clinical situations where biopsy material is inadequate or unavailable and where it leads to fewer tissue biopsies.
引用
- Oellerich M, Christenson RH, Beck J, et al. Plasma EGFR mutation testing in non-small cell lung cancer: A value proposition. Clin Chim Acta. 2019. PMID: 31125533. doi:10.1016/j.cca.2019.05.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。